S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Forecast, Price & News

$0.50
+0.02 (+4.17%)
(As of 05/23/2022 10:49 AM ET)
Add
Compare
Today's Range
$0.49
$0.50
50-Day Range
$0.42
$0.85
52-Week Range
$0.41
$5.63
Volume
801 shs
Average Volume
611,513 shs
Market Capitalization
$62.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.2
30 days | 90 days | 365 days | Advanced Chart
Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Orchard Therapeutics logo

About Orchard Therapeutics

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Headlines

Orchard Therapeutics Q1 2022 Earnings Preview
Orchard Therapeutics Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORTX
Fax
N/A
Employees
259
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.67 million
Book Value
$1.40 per share

Profitability

Net Income
$-144.58 million
Pretax Margin
-2,137.78%

Debt

Price-To-Earnings

Miscellaneous

Free Float
122,883,000
Market Cap
$62.95 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/30/2022
Today
5/23/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.21 out of 5 stars

Medical Sector

356th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

56th out of 210 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Orchard Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares.
View analyst ratings for Orchard Therapeutics
or view top-rated stocks.

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 777,900 shares, a drop of 48.8% from the April 15th total of 1,520,000 shares. Based on an average trading volume of 582,300 shares, the short-interest ratio is presently 1.3 days. Currently, 0.7% of the company's shares are sold short.
View Orchard Therapeutics' Short Interest
.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Orchard Therapeutics
.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) posted its quarterly earnings data on Wednesday, March, 30th. The company reported ($0.29) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.29). The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.65 million. During the same quarter last year, the company posted ($0.34) EPS.
View Orchard Therapeutics' earnings history
.

What price target have analysts set for ORTX?

6 Wall Street analysts have issued 12-month price targets for Orchard Therapeutics' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate Orchard Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,700.0% from the stock's current price.
View analysts' price targets for Orchard Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?
Orchard Therapeutics' management team includes the following people:
  • Dr. Bobby Gaspar Ph.D., M.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 57, Pay $712.41k)
  • Mr. Frank E. Thomas, Pres & COO (Age 52, Pay $586.18k)
  • Dr. Nicoletta Loggia Ph.D., Chief Technical Officer
  • Dr. Fulvio Mavilio Ph.D., Chief Scientific Officer
  • Ms. Renee T. Leck, Director of Investor Relations
  • Benjamin Navon, Director of Corp. Communications
  • Mr. John Cerio, Chief Human Resource Officer
  • Dr. Anne Dupraz-Poiseau, Chief Devel. Officer
  • Mr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial Operations
  • Mr. Braden Parker, Chief Commercial Officer
What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.35%), SG Americas Securities LLC (0.84%), Renaissance Technologies LLC (0.65%), BlackRock Inc. (0.60%), GSA Capital Partners LLP (0.30%) and New York State Common Retirement Fund (0.26%). Company insiders that own Orchard Therapeutics stock include Bobby Gaspar, Fmr Llc and Frank E Thomas.
View institutional ownership trends for Orchard Therapeutics
.

Which institutional investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Renaissance Technologies LLC, JPMorgan Chase & Co., Sei Investments Co., Group One Trading L.P., Harbor Capital Advisors Inc., Goldman Sachs Group Inc., and Simplex Trading LLC.
View insider buying and selling activity for Orchard Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Orchard Therapeutics stock?

ORTX stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Forefront Analytics LLC, and GSA Capital Partners LLP. Company insiders that have bought Orchard Therapeutics stock in the last two years include Bobby Gaspar, and Frank E Thomas.
View insider buying and selling activity for Orchard Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $0.50.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $62.95 million and generates $1.67 million in revenue each year. The company earns $-144.58 million in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 259 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 442038088286.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.